Tibsovo(ivosidenib)
Tibsovo (ivosidenib) is a small molecule pharmaceutical. Ivosidenib was first approved as Tibsovo on 2018-07-20. It is used to treat myeloid leukemia acute in the USA. It has been approved in Europe to treat cholangiocarcinoma and myeloid leukemia acute. The pharmaceutical is active against isocitrate dehydrogenase [NADP] cytoplasmic.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
Trade Name
FDA
EMA
Tibsovo
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tibsovo | New Drug Application | 2024-09-16 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| myeloid leukemia acute | — | D015470 | C92.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
IVOSIDENIB, TIBSOVO, SERVIER | |||
| 2030-10-24 | ODE-447 | ||
| 2028-08-25 | ODE-368 | ||
| 2026-10-24 | I-924 | ||
| 2026-05-02 | ODE-242 | ||
| 2025-07-20 | ODE-203 | ||
| 2025-05-25 | I-893 | ||
| 2024-08-25 | I-875 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Ivosidenib, Tibsovo, Servier | |||
| 10980788 | 2039-06-07 | U-3112, U-3113, U-3214, U-3383, U-3743 | |
| 10653710 | 2036-10-18 | U-3387 | |
| 9968595 | 2035-03-13 | DP | U-2351, U-2533, U-2534, U-3384 |
| 10449184 | 2035-03-13 | DP | |
| 10799490 | 2035-03-13 | DP | U-2981, U-2982, U-3384 |
| 9474779 | 2033-08-19 | DS, DP | U-2350, U-2533, U-2534, U-3213, U-3386, U-3742 |
| 9850277 | 2033-01-18 | DS, DP | U-2350, U-2533, U-2534, U-3213, U-3386, U-3742 |
| 10717764 | 2033-01-18 | U-3215 | |
| 11667673 | 2033-01-18 | U-3742 | |
| 10610125 | 2030-06-21 | U-2784, U-2785, U-3385 | |
HCPCS
No data
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 1 | 1 | — | 1 | 3 |
| Leukemia | D007938 | — | C95 | — | 1 | 1 | — | — | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 1 | 1 | — | — | 2 |
| Myeloid leukemia | D007951 | — | C92 | — | 1 | 1 | — | — | 2 |
| Biliary tract neoplasms | D001661 | — | C24.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematopoietic stem cell transplantation | D018380 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ivosidenib |
| INN | ivosidenib |
| Description | Ivosidenib is a tertiary carboxamide resulting from the formal condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is approved by the FDA for the treatment of acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-1 (IDH1) mutation. It has a role as an antineoplastic agent and an EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor. It is a member of monochlorobenzenes, a cyanopyridine, a member of pyrrolidin-2-ones, an organofluorine compound, a tertiary carboxamide and a secondary carboxamide. |
| Classification | Small molecule |
| Drug class | mutated isocitrate dehydrogenase (IDH) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1 |
Identifiers
| PDB | — |
| CAS-ID | 1448347-49-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989958 |
| ChEBI ID | — |
| PubChem CID | 71657455 |
| DrugBank | DB14568 |
| UNII ID | Q2PCN8MAM6 (ChemIDplus, GSRS) |
Target
Agency Approved
IDH1
IDH1
Organism
Homo sapiens
Gene name
IDH1
Gene synonyms
PICD
NCBI Gene ID
Protein name
isocitrate dehydrogenase [NADP] cytoplasmic
Protein synonyms
Cytosolic NADP-isocitrate dehydrogenase, epididymis luminal protein 216, epididymis secretory protein Li 26, epididymis secretory sperm binding protein, IDPc, isocitrate dehydrogenase (NADP(+)) 1, cytosolic, isocitrate dehydrogenase 1 (NADP+), soluble, NADP(+)-specific ICDH, NADP-dependent isocitrate dehydrogenase, cytosolic, NADP-dependent isocitrate dehydrogenase, peroxisomal, Oxalosuccinate decarboxylase
Uniprot ID
Mouse ortholog
Idh1 (15926)
isocitrate dehydrogenase [NADP] cytoplasmic (Q3UAV7)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,481 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tibsovo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,480 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use